close

Main navigation

close
Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Industry Insights 2015 to 2031

  • 22482

  • Upcoming

  • NA

  • PDF

    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★

Select License

  • It allows one person, the buyer, to have sole right and access to the purchased report. Further distribution of product is strictly prohibited.
  • It allows the purchased product to be shared among 5 people within your organization at maximum.
  • It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.
Request sample

  • Multiple sclerosis is a chronic disease affecting the central nervous system, i.e., the brain, spinal cord, and optic nerves. This leads to a wide range of symptoms of MS in the body. The disorder destroys the myelin that surrounds and protects axons (nerve fibers). The damage results in disruption of nerve impulses (messages) from the central nervous system causing loss of body functions.

    Request Covid - 19 Impact

    Demand for Multiple Sclerosis Drugs from 2015 to 2020 Vs Future Market Projections for 2021-2031

    From 2015 to 2020, sales of multiple sclerosis drugs were significantly high, expanding at under 5.8% CAGR.  The development of novel therapies for treating multiple sclerosis and pipeline therapeutics has strengthened the manufacturers operating in the target market. These are some of the factors expected to fuel the growth of the global multiple sclerosis drugs market.

    The COVID-19 pandemic has affected the research and development spending on various chronic diseases to a certain extent.  The prevalence of COVID-19 in MS patients has increased in recent times and is expected to boost the demand for multiple sclerosis drugs over the forecast years.

    Global Multiple Sclerosis Drugs Market Revenue Outlook:

    The global multiple sclerosis drugs market was valued at US$ 27.5 Bn in 2020 and is projected to register а САGR of 6.5% by 2031.

    Nonetheless, various industry players in the global multiple sclerosis drugs markets are now increasingly focusing on establishing successful collaborations, acquisitions, and joint venture activities to enhance their respective customer bases. In doing so, these players are also growing their supply capabilities to meet customer requirements on a local and global scale. This factor, paired with promising industrialization prospects in developing economies of the Asia-Pacific region, such as China, India, Taiwan, Indonesia, etc., are expected to create massive business opportunities for key players over the forecast period.

    The Increasing Prevalence Of Autoimmune Diseases Is Expected To Boost The Multiple Sclerosis Drugs Sales

    Multiple sclerosis is a chronic disorder affecting the central nervous system, including the brain, spinal cord, and optic nerves. Autoimmune diseases caused low or high activities in the immune system. The epidemiology of multiple sclerosis has increased in many countries globally and has led to new revenue growth opportunities for the manufacturers of multiple sclerosis drugs. Increasing demographic dividends, surging per capita disposable incomes, and higher investments towards the medical sector are also crucial factors anticipated to further augment market growth over the forecast period.

    Estimated Prevalence & Incidence Of Multiple Sclerosis Per 100,000

    Region Incidence Prevalence
    Global – 30.1
    Argentina – 36–40
    Canada – 180–266
    Latin America & Caribbean 0.6–1.9 5–30
    Mexico 15–18 7.5–30
    US – 272–377
    Southern California Hispanic/ Latinx People 2.9 –
    Southern California White People 6.9 –
    Puerto Rico 5.5 68.8

    To learn more about this report, request for sample report

    What Are The Key Challenges For Manufacturers Of Multiple Sclerosis Drugs?

    The side effects of various drugs used in treating multiple sclerosis drugs include fever, shortness of breath, rapid heartbeat, anxiety, and severe side effects to the musculoskeletal, respiratory, urogenital systems. The start of the COVID-19 pandemic has caused either shutdown of numerous businesses or their operation with minimal staff and the disturbance faced by various sourcing, manufacture and supply-chain operations, resulting in irreversible damage to each region's respective economic landscape. This is also expected to have a profoundly adverse impact on the multiple sclerosis treatment markets as well. The lockdown restricted the manufacturing and import/export of medicines. Conversely, as obligatory lockdowns are slowly relaxed, and economies begin to reopen again, manufacturing will start for drugs and biologics, this market is expected to recover moderately.

    Novel Opportunities For New & Existing Players Of Multiple Sclerosis Drugs

    The ongoing clinical trials and recent advancements in MS (Multiple Sclerosis) coupled with new products approved by the FDA are some of the factors expected to create lucrative opportunities for existing and new market entrants to expand and cater to the demand.

    • In March 2021, FDA approved Oral Ponvory™(Ponesimod) for Relapsing For MS
    • In April 2021 FDA approved a portable nerve stimulator for use during physical therapy to treat walking probleMS in people with MS

    Various Growth Strategies Adopted By Players Operating In The Multiple Sclerosis Drugs Market

    Increasing focus on growth strategies such as new product launches, mergers & acquisitions, partnerships, higher investments for product enhancements, etc., are trends currently witnessed in this market. These joint ventures and strategic expansion help organizations improve their offering to treat MS and its types.

    • In September 2020, Sanofi announced the complete acquisition of Principia Biopharma Inc., which augmented its small molecule research capabilities.
    • In July 2019, Teva Pharmaceuticals USA, Inc., an Isreal–based company, launched Copaxone – prefilled autoinjector YpsoMate.

    List Of Some FDA Approved Multiple Sclerosis Drugs With An Approved Indication

    Generic Name Commercial Name Approved Indication
    Dimethyl fumarate Tecfidera Clinically isolated syndrome & Relapsing MS
    Fingolimod Gilenya Clinically isolated syndrome & Relapsing MS
    Siponimod Mayzent Clinically isolated syndrome & Relapsing MS
    Teriflunomide Aubagio Clinically isolated syndrome & Relapsing-remitting MS
    Cladribine Mavenclad Relapsing MS
    Glatiramer acetate (GA) Copaxone Clinically isolated syndrome & Relapsing remitting MS
    Interferons Avonex, Rebif, Plegridy, Betaseron, Betaferon, Extavia Clinically isolated syndrome & Relapsing remitting MS
    Alemtuzumab Lemtrada Aggressive relapsing remitting MS
    Mitoxantrone Novantrone Aggressive relapsing remitting MS, Secondary progressive MS & Progressive relapsing MS
    Natalizumab Tysabri Relapsing remitting MS
    Ocrelizumab Ocrevus Relapsing remitting MS & Primary progressive MS

    To learn more about this report, request for sample report

    Country-Wise Analysis

    Why Is Multiple Sclerosis Drugs Sales Higher In North America?

    The North American market for multiple sclerosis drugs is expected to register a higher share than other regions. According to WHO data published in 2019, approximately 1 Mn patients live with multiple sclerosis in the United States and is likely to more than double by the year 2025.

    Competitive Landscape

    The multiple sclerosis drugs landscape appears highly consolidated, with a major chunk of it being dominated by players.

    • Bristol-Myers Squibb Company
    • Sanofi
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Hoffmann-La Roche Ltd.
    • Biogen
    • Other Players

    Some Notable Developments In The Market Include:

    • In Sept 2020, Dr. Reddy's Laboratories launched Dimethyl Fumarate delayed-release capsules which are used to treat multiple sclerosis (MS) in the US market.
    • In March 2019, Novartis AG received FDA approval for Mayzent for patients suffering from active secondary progressive MS.
    • In March 2019, TG Therapeutics, Inc. announced the outcomes from the phase 2 clinical studies on an anti-CD20 monoclonal antibody, ublituximab (TG-1101) is in the development process for MS treatment.

    Report Scope

    • Forecast Period: 2022-2031
    • Actual Year: 2021
    • Historical Data Available for: 2015-2020

    Key Regions Covered

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

    Key Segments Covered

    Multiple Sclerosis Drugs Market, By Drug Class

    • Interferon Beta
    • Sphingosine 1 Phosphate Receptor Modulators
    • NF-KB Inhibitor
    • Corticosteroids
    • Adrenocorticotropic Hormone
    • Other Drug Class

    Multiple Sclerosis Drugs Market, By Type

    • Relapsing–Remitting Multiple Sclerosis (RRMS)
    • Secondary Progressive Multiple Sclerosis (SPMS)
    • Primary Progressive Multiple Sclerosis (PPMS)
    • Severe Relapsing-Remitting Multiple Sclerosis (RES)

    Multiple Sclerosis Drugs Market, By Treatment Type

    • Preventive Therapies
    • Abortive Therapies
    • Symptomatic Therapies

    Multiple Sclerosis Drugs Market, By Route of Administration

    • IV Route
    • Oral

    Multiple Sclerosis Drugs Market, By End Users

    • Hospitals
    • Clinics
    • Other End-Users
    Particular Scope
    Region

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    Historical Period 2015-2020
    Base Year 2021
    Forecast Period 2022–2031
    Revenue in US$ Mn

    To learn more about this report, request for sample report

    • Bristol-Myers Squibb Company
    • Sanofi
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Hoffmann-La Roche Ltd.
    • Biogen
    • Other Players
    • Chapter 1 Global Multiple Sclerosis Drugs Market Outlook
      • 1.1 Introduction
      • 1.2 Segmentation of Multiple Sclerosis Drugs Market Based On Drug Class, Type, Treatment Type, Route of Administration, & End Users and Region
      • 1.3 Drivers
      • 1.4 Restraints
      • 1.5 Opportunities
      • 1.6 Trends
      • 1.7 Macro-economic Factors
      • 1.8 Regulatory Framework
      • 1.9 Global Multiple Sclerosis Drugs Market Pricing Analysis by Region, 2020
      • 1.10 Opportunity Map Analysis
        • 1.10.1 Optimistic Scenario
        • 1.10.2 Likely Scenario
        • 1.10.3 Conservative Scenario
      • 1.11 Opportunity Orbits
      • 1.12 Market Investment Feasibility Index
      • 1.13 PEST Analysis
      • 1.14 PORTER’S Five Force Analysis
      • 1.15 Drivers & Restraints Impact Analysis
      • 1.16 Marketing Strategy
      • 1.17 Product Life Cycle Analysis
      • 1.18 Value Chain Analysis
      • 1.19 Cost Structure Analysis
      • 1.20 Regional Market Share and BPS Analysis in Multiple Sclerosis Drugs Market
      • 1.21 COVID-19 Impact Analysis
    • Chapter 2 Global Multiple Sclerosis Drugs Market Overview
      • 2.1 Global Market Value & Volume Comparison by Drug Class (2015-2031)
        • 2.1.1 Global Market Value & Volume Market Share by Drug Class in 2021
        • 2.1.2 Global Market Attractiveness Analysis by Drug Class , 2015–2022
      • 2.2 Global Market Value & Volume Comparison by Type (2015-2031)
        • 2.2.1 Global Market Value & Volume Market Share by Type in 2021
        • 2.2.2 Global Market Attractiveness Analysis by Type , 2015–2022
      • 2.3 Global Market by Treatment Type
        • 2.3.1 Global Market Value & Volume Comparison by Treatment Type (2015-2031)
        • 2.3.2 Global Market Value & Volume Market Share by Treatment Type in 2021
        • 2.3.3 Global Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 2.4 Global Market Value & Volume Comparison by Route of Administration (2015-2031)
        • 2.4.1 Global Market Value & Volume Market Share by Route of Administration in 2021
        • 2.4.2 Global Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 2.5 Global Market Value & Volume Comparison by End Users (2014-2030)
        • 2.5.1 Global Market Value & Volume Market Share by End Users in 2021
        • 2.5.2 Global Market Attractiveness Analysis by End Users , 2015–2022
      • 2.6 Global Market Outlook by Region
        • 2.6.1 Global Market Value & Volume Comparison by Region (2015-2031)
        • 2.6.2 Global Market Value & Volume Market Share by Region in 2021
        • 2.6.3 Global Market Attractiveness Analysis by Region, 2015–2022
      • 2.7 Global Market Outlook (2015-2031)
        • 2.7.1 Global Market Value & Volume (2015–2022)
        • 2.7.2 Global Market Value & Volume (2023-2031)
      • 2.8 Global Market Value & Volume by Regions
        • 2.8.1 Global Market Value & Volume Comparison by Region (2015–2022)
        • 2.8.2 Global Market Value & Volume Comparison by Region (2023-2031)
      • 2.9 Global Market Value & Volume by Drug Class
        • 2.9.1 Global Market Value & Volume Comparison by Drug Class (2015–2022)
        • 2.9.2 Global Market Value & Volume Comparison by Drug Class (2023-2031)
      • 2.10 Global Market Value & Volume by Type
        • 2.10.1 Global Market Value & Volume Comparison by Type (2015–2022)
        • 2.10.2 Global Market Value & Volume Comparison by Type (2023-2031)
      • 2.11 Global Market Value & Volume by Treatment Type
        • 2.12.1 Global Market Value & Volume Comparison by Treatment Type (2015–2022)
        • 2.11.2 Global Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 2.12 Global Market Value & Volume by Route of Administration
        • 2.12.1 Global Market Value & Volume Comparison by Route of Administration (2015–2022)
        • 2.12.2 Global Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 2.13 Global Market Value & Volume by End Users
        • 2.13.1 Global Market Value & Volume Comparison by End Users (2015–2022)
        • 2.13.2 Global Market Value & Volume Comparison by End Users (2023-2031)
      • 2.14 Global Market Y-o-Y Growth Rate Comparison 2016–2031
        • 2.14.1 Global Market Y-o-Y Growth Rate by Region
        • 2.14.2 Global Market Y-o-Y Growth Rate by Drug Class
        • 2.14.3 Global Market Y-o-Y Growth Rate by Type
        • 2.14.4 Global Market Y-o-Y Growth Rate by Treatment Type
        • 2.14.5 Global Market Y-o-Y Growth Rate by Route of Administration
        • 2.14.6 Global Market Y-o-Y Growth Rate by End Users
      • 2.15 Global Market Share Comparison 2015–2031
        • 2.15.1 Global Market Share by Region
        • 2.15.2 Global Market Share by Drug Class
        • 2.15.3 Global Market Share by Type
        • 2.15.4 Global Market Share by Treatment Type
        • 2.15.5 Global Market Share by Route of Administration
        • 2.15.6 Global Market Share by End Users
    • Chapter 3 North America Multiple Sclerosis Drugs Market Overview
      • 3.1 North America Market by Drug Class
        • 3.1.1 North America Market Value & Volume Comparison by Drug Class (2015-2031)
        • 3.1.2 North America Market Value & Volume Market Share by Drug Class in 2021
      • 3.2 North America Market Value & Volume Comparison by Type (2015-2031)
        • 3.2.1 North America Market Value & Volume Market Share by Type in 2021
        • 3.2.2 North America Market Attractiveness Analysis by Type , 2015–2022
      • 3.3 North America Market by Treatment Type
        • 3.3.1 North America Market Value & Volume Comparison by Treatment Type (2015-2031)
        • 3.3.2 North America Market Value & Volume Market Share by Treatment Type in 2021
        • 3.3.3 North America Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 3.4 North America Market Value & Volume Comparison by Route of Administration (2015-2031)
        • 3.4.1 North America Market Value & Volume Market Share by Route of Administration in 2021
        • 3.4.2 North America Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 3.5 North America Market Value & Volume Comparison by End Users (2014-2030)
        • 3.5.1 North America Market Value & Volume Market Share by End Users in 2021
        • 3.5.2 North America Market Attractiveness Analysis by End Users , 2015–2022
      • 3.6 North America Market Outlook by Region
        • 3.6.1 North America Market Value & Volume Comparison by Region (2015-2031)
        • 3.6.2 North America Market Value & Volume Market Share by Region in 2021
        • 3.6.3 North America Market Attractiveness Analysis by Region, 2015–2022
      • 3.7 North America Market Outlook (2015-2031)
        • 3.7.1 North America Market Value & Volume (2015–2022)
        • 3.7.2 North America Market Value & Volume (2023-2031)
      • 3.8 North America Market Value & Volume by Regions
        • 3.8.1 North America Market Value & Volume Comparison by Region (2015–2022)
        • 3.8.2 North America Market Value & Volume Comparison by Region (2023-2031)
      • 3.9 North America Market Value & Volume by Drug Class
        • 3.9.1 North America Market Value & Volume Comparison by Drug Class (2015–2022)
        • 3.9.2 North America Market Value & Volume Comparison by Drug Class (2023-2031)
      • 3.10 North America Market Value & Volume by Type
        • 3.10.1 North America Market Value & Volume Comparison by Type (2015–2022)
        • 3.10.2 North America Market Value & Volume Comparison by Type (2023-2031)
      • 3.11 North America Market Value & Volume by Treatment Type
        • 3.12.1 North America Market Value & Volume Comparison by Treatment Type (2015–2022)
        • 3.11.2 North America Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 3.12 North America Market Value & Volume by Route of Administration
        • 3.12.1 North America Market Value & Volume Comparison by Route of Administration (2015–2022)
        • 3.12.2 North America Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 3.13 North America Market Value & Volume by End Users
        • 3.13.1 North America Market Value & Volume Comparison by End Users (2015–2022)
        • 3.13.2 North America Market Value & Volume Comparison by End Users (2023-2031)
      • 3.14 North America Market Y-o-Y Growth Rate Comparison 2016–2031
        • 3.14.1 North America Market Y-o-Y Growth Rate by Region
        • 3.14.2 North America Market Y-o-Y Growth Rate by Drug Class
        • 3.14.3 North America Market Y-o-Y Growth Rate by Type
        • 3.14.4 North America Market Y-o-Y Growth Rate by Treatment Type
        • 3.14.5 North America Market Y-o-Y Growth Rate by Route of Administration
        • 3.14.6 North America Market Y-o-Y Growth Rate by End Users
      • 3.15 North America Market Share Comparison 2015–2031
        • 3.15.1 North America Market Share by Region
        • 3.15.2 North America Market Share by Drug Class
        • 3.15.3 North America Market Share by Type
        • 3.15.4 North America Market Share by Treatment Type
        • 3.15.5 North America Market Share by Route of Administration
        • 3.15.6 North America Market Share by End Users
    • Chapter 4 Europe Multiple Sclerosis Drugs Market Overview
      • 4.1 Europe Market by Drug Class
        • 4.1.1 Europe Market Value & Volume Comparison by Drug Class (2015-2031)
        • 4.1.2 Europe Market Value & Volume Market Share by Drug Class in 2021
      • 4.2 Europe Market Value & Volume Comparison by Type (2015-2031)
        • 4.2.1 Europe Market Value & Volume Market Share by Type in 2021
        • 4.2.2 Europe Market Attractiveness Analysis by Type , 2015–2022
      • 4.3 Europe Market by Treatment Type
        • 4.3.1 Europe Market Value & Volume Comparison by Treatment Type (2015-2031)
        • 4.3.2 Europe Market Value & Volume Market Share by Treatment Type in 2021
        • 4.3.3 Europe Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 4.4 Europe Market Value & Volume Comparison by Route of Administration (2015-2031)
        • 4.4.1 Europe Market Value & Volume Market Share by Route of Administration in 2021
        • 4.4.2 Europe Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 4.5 Europe Market Value & Volume Comparison by End Users (2014-2030)
        • 4.5.1 Europe Market Value & Volume Market Share by End Users in 2021
        • 4.5.2 Europe Market Attractiveness Analysis by End Users , 2015–2022
      • 4.6 Europe Market Outlook by Region
        • 4.6.1 Europe Market Value & Volume Comparison by Region (2015-2031)
        • 4.6.2 Europe Market Value & Volume Market Share by Region in 2021
        • 4.6.3 Europe Market Attractiveness Analysis by Region, 2015–2022
      • 4.7 Europe Market Outlook (2015-2031)
        • 4.7.1 Europe Market Value & Volume (2015–2022)
        • 4.7.2 Europe Market Value & Volume (2023-2031)
      • 4.8 Europe Market Value & Volume by Regions
        • 4.8.1 Europe Market Value & Volume Comparison by Region (2015–2022)
        • 4.8.2 Europe Market Value & Volume Comparison by Region (2023-2031)
      • 4.9 Europe Market Value & Volume by Drug Class
        • 4.9.1 Europe Market Value & Volume Comparison by Drug Class (2015–2022)
        • 4.9.2 Europe Market Value & Volume Comparison by Drug Class (2023-2031)
      • 4.10 Europe Market Value & Volume by Type
        • 4.10.1 Europe Market Value & Volume Comparison by Type (2015–2022)
        • 4.10.2 Europe Market Value & Volume Comparison by Type (2023-2031)
      • 4.11 Europe Market Value & Volume by Treatment Type
        • 4.12.1 Europe Market Value & Volume Comparison by Treatment Type (2015–2022)
        • 4.11.2 Europe Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 4.12 Europe Market Value & Volume by Route of Administration
        • 4.12.1 Europe Market Value & Volume Comparison by Route of Administration (2015–2022)
        • 4.12.2 Europe Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 4.13 Europe Market Value & Volume by End Users
        • 4.13.1 Europe Market Value & Volume Comparison by End Users (2015–2022)
        • 4.13.2 Europe Market Value & Volume Comparison by End Users (2023-2031)
      • 4.14 Europe Market Y-o-Y Growth Rate Comparison 2016–2031
        • 4.14.1 Europe Market Y-o-Y Growth Rate by Region
        • 4.14.2 Europe Market Y-o-Y Growth Rate by Drug Class
        • 4.14.3 Europe Market Y-o-Y Growth Rate by Type
        • 4.14.4 Europe Market Y-o-Y Growth Rate by Treatment Type
        • 4.14.5 Europe Market Y-o-Y Growth Rate by Route of Administration
        • 4.14.6 Europe Market Y-o-Y Growth Rate by End Users
      • 4.15 Europe Market Share Comparison 2015–2031
        • 4.15.1 Europe Market Share by Region
        • 4.15.2 Europe Market Share by Drug Class
        • 4.15.3 Europe Market Share by Type
        • 4.15.4 Europe Market Share by Treatment Type
        • 4.15.5 Europe Market Share by Route of Administration
        • 4.15.6 Europe Market Share by End Users
    • Chapter 5 Asia-Pacific Multiple Sclerosis Drugs Market Overview
      • 5.1 Asia-Pacific Market by Drug Class
      • 5.1.1 Asia-Pacific Market Value & Volume Comparison by Drug Class (2015-2031)
      • 5.1.2 Asia-Pacific Market Value & Volume Market Share by Drug Class in 2021
      • 5.2 Asia-Pacific Market Value & Volume Comparison by Type (2015-2031)
      • 5.2.1 Asia-Pacific Market Value & Volume Market Share by Type in 2021
      • 5.2.2 Asia-Pacific Market Attractiveness Analysis by Type , 2015–2022
      • 5.3 Asia-Pacific Market by Treatment Type
      • 5.3.1 Asia-Pacific Market Value & Volume Comparison by Treatment Type (2015-2031)
      • 5.3.2 Asia-Pacific Market Value & Volume Market Share by Treatment Type in 2021
      • 5.3.3 Asia-Pacific Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 5.4 Asia-Pacific Market Value & Volume Comparison by Route of Administration (2015-2031)
      • 5.4.1 Asia-Pacific Market Value & Volume Market Share by Route of Administration in 2021
      • 5.4.2 Asia-Pacific Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 5.5 Asia-Pacific Market Value & Volume Comparison by End Users (2014-2030)
      • 5.5.1 Asia-Pacific Market Value & Volume Market Share by End Users in 2021
      • 5.5.2 Asia-Pacific Market Attractiveness Analysis by End Users , 2015–2022
      • 5.6 Asia-Pacific Market Outlook by Region
      • 5.6.1 Asia-Pacific Market Value & Volume Comparison by Region (2015-2031)
      • 5.6.2 Asia-Pacific Market Value & Volume Market Share by Region in 2021
      • 5.6.3 Asia-Pacific Market Attractiveness Analysis by Region, 2015–2022
      • 5.7 Asia-Pacific Market Outlook (2015-2031)
      • 5.7.1 Asia-Pacific Market Value & Volume (2015–2022)
      • 5.7.2 Asia-Pacific Market Value & Volume (2023-2031)
      • 5.8 Asia-Pacific Market Value & Volume by Regions
      • 5.8.1 Asia-Pacific Market Value & Volume Comparison by Region (2015–2022)
      • 5.8.2 Asia-Pacific Market Value & Volume Comparison by Region (2023-2031)
      • 5.9 Asia-Pacific Market Value & Volume by Drug Class
      • 5.9.1 Asia-Pacific Market Value & Volume Comparison by Drug Class (2015–2022)
      • 5.9.2 Asia-Pacific Market Value & Volume Comparison by Drug Class (2023-2031)
      • 5.10 Asia-Pacific Market Value & Volume by Type
      • 5.10.1 Asia-Pacific Market Value & Volume Comparison by Type (2015–2022)
      • 5.10.2 Asia-Pacific Market Value & Volume Comparison by Type (2023-2031)
      • 5.11 Asia-Pacific Market Value & Volume by Treatment Type
      • 5.12.1 Asia-Pacific Market Value & Volume Comparison by Treatment Type (2015–2022)
      • 5.11.2 Asia-Pacific Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 5.12 Asia-Pacific Market Value & Volume by Route of Administration
      • 5.12.1 Asia-Pacific Market Value & Volume Comparison by Route of Administration (2015–2022)
      • 5.12.2 Asia-Pacific Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 5.13 Asia-Pacific Market Value & Volume by End Users
      • 5.13.1 Asia-Pacific Market Value & Volume Comparison by End Users (2015–2022)
      • 5.13.2 Asia-Pacific Market Value & Volume Comparison by End Users (2023-2031)
      • 5.14 Asia-Pacific Market Y-o-Y Growth Rate Comparison 2016–2031
      • 5.14.1 Asia-Pacific Market Y-o-Y Growth Rate by Region
      • 5.14.2 Asia-Pacific Market Y-o-Y Growth Rate by Drug Class
      • 5.14.3 Asia-Pacific Market Y-o-Y Growth Rate by Type
      • 5.14.4 Asia-Pacific Market Y-o-Y Growth Rate by Treatment Type
      • 5.14.5 Asia-Pacific Market Y-o-Y Growth Rate by Route of Administration
      • 5.14.6 Asia-Pacific Market Y-o-Y Growth Rate by End Users
      • 5.15 Asia-Pacific Market Share Comparison 2015–2031
      • 5.15.1 Asia-Pacific Market Share by Region
      • 5.15.2 Asia-Pacific Market Share by Drug Class
      • 5.15.3 Asia-Pacific Market Share by Type
      • 5.15.4 Asia-Pacific Market Share by Treatment Type
      • 5.15.5 Asia-Pacific Market Share by Route of Administration
      • 5.15.6 Asia-Pacific Market Share by End Users
    • Chapter 6 South America Multiple Sclerosis Drugs Market Overview
      • 6.1 South America Market by Drug Class
        • 6.1.1 South America Market Value & Volume Comparison by Drug Class (2015-2031)
        • 6.1.2 South America Market Value & Volume Market Share by Drug Class in 2021
      • 6.2 South America Market Value & Volume Comparison by Type (2015-2031)
        • 6.2.1 South America Market Value & Volume Market Share by Type in 2021
        • 6.2.2 South America Market Attractiveness Analysis by Type , 2015–2022
      • 6.3 South America Market by Treatment Type
        • 6.3.1 South America Market Value & Volume Comparison by Treatment Type (2015-2031)
        • 6.3.2 South America Market Value & Volume Market Share by Treatment Type in 2021
        • 6.3.3 South America Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 6.4 South America Market Value & Volume Comparison by Route of Administration (2015-2031)
        • 6.4.1 South America Market Value & Volume Market Share by Route of Administration in 2021
        • 6.4.2 South America Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 6.5 South America Market Value & Volume Comparison by End Users (2014-2030)
        • 6.5.1 South America Market Value & Volume Market Share by End Users in 2021
        • 6.5.2 South America Market Attractiveness Analysis by End Users , 2015–2022
      • 6.6 South America Market Outlook by Region
        • 6.6.1 South America Market Value & Volume Comparison by Region (2015-2031)
        • 6.6.2 South America Market Value & Volume Market Share by Region in 2021
        • 6.6.3 South America Market Attractiveness Analysis by Region, 2015–2022
      • 6.7 South America Market Outlook (2015-2031)
        • 6.7.1 South America Market Value & Volume (2015–2022)
        • 6.7.2 South America Market Value & Volume (2023-2031)
      • 6.8 South America Market Value & Volume by Regions
        • 6.8.1 South America Market Value & Volume Comparison by Region (2015–2022)
        • 6.8.2 South America Market Value & Volume Comparison by Region (2023-2031)
      • 6.9 South America Market Value & Volume by Drug Class
        • 6.9.1 South America Market Value & Volume Comparison by Drug Class (2015–2022)
        • 6.9.2 South America Market Value & Volume Comparison by Drug Class (2023-2031)
      • 6.10 South America Market Value & Volume by Type
        • 6.10.1 South America Market Value & Volume Comparison by Type (2015–2022)
        • 6.10.2 South America Market Value & Volume Comparison by Type (2023-2031)
      • 6.11 South America Market Value & Volume by Treatment Type
        • 6.12.1 South America Market Value & Volume Comparison by Treatment Type (2015–2022)
        • 6.11.2 South America Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 6.12 South America Market Value & Volume by Route of Administration
        • 6.12.1 South America Market Value & Volume Comparison by Route of Administration (2015–2022)
        • 6.12.2 South America Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 6.13 South America Market Value & Volume by End Users
        • 6.13.1 South America Market Value & Volume Comparison by End Users (2015–2022)
        • 6.13.2 South America Market Value & Volume Comparison by End Users (2023-2031)
      • 6.14 South America Market Y-o-Y Growth Rate Comparison 2016–2031
        • 6.14.1 South America Market Y-o-Y Growth Rate by Region
        • 6.14.2 South America Market Y-o-Y Growth Rate by Drug Class
        • 6.14.3 South America Market Y-o-Y Growth Rate by Type
        • 6.14.4 South America Market Y-o-Y Growth Rate by Treatment Type
        • 6.14.5 South America Market Y-o-Y Growth Rate by Route of Administration
        • 6.14.6 South America Market Y-o-Y Growth Rate by End Users
      • 6.15 South America Market Share Comparison 2015–2031
        • 6.15.1 South America Market Share by Region
        • 6.15.2 South America Market Share by Drug Class
        • 6.15.3 South America Market Share by Type
        • 6.15.4 South America Market Share by Treatment Type
        • 6.15.5 South America Market Share by Route of Administration
        • 6.15.6 South America Market Share by End Users
    • Chapter 7 MEA Multiple Sclerosis Drugs Market Overview
      • 7.1 MEA Market by Drug Class
        • 7.1.1 MEA Market Value & Volume Comparison by Drug Class (2015-2031)
        • 7.1.2 MEA Market Value & Volume Market Share by Drug Class in 2021
      • 7.2 MEA Market Value & Volume Comparison by Type (2015-2031)
        • 7.2.1 MEA Market Value & Volume Market Share by Type in 2021
        • 7.2.2 MEA Market Attractiveness Analysis by Type , 2015–2022
      • 7.3 MEA Market by Treatment Type
        • 7.3.1 MEA Market Value & Volume Comparison by Treatment Type (2015-2031)
        • 7.3.2 MEA Market Value & Volume Market Share by Treatment Type in 2021
        • 7.3.3 MEA Market Attractiveness Analysis by Treatment Type , 2015–2022
      • 7.4 MEA Market Value & Volume Comparison by Route of Administration (2015-2031)
        • 7.4.1 MEA Market Value & Volume Market Share by Route of Administration in 2021
        • 7.4.2 MEA Market Attractiveness Analysis by Route of Administration , 2015–2022
      • 7.5 MEA Market Value & Volume Comparison by End Users (2014-2030)
        • 7.5.1 MEA Market Value & Volume Market Share by End Users in 2021
        • 7.5.2 MEA Market Attractiveness Analysis by End Users , 2015–2022
      • 7.6 MEA Market Outlook by Region
        • 7.6.1 MEA Market Value & Volume Comparison by Region (2015-2031)
        • 7.6.2 MEA Market Value & Volume Market Share by Region in 2021
        • 7.6.3 MEA Market Attractiveness Analysis by Region, 2015–2022
      • 7.7 MEA Market Outlook (2015-2031)
        • 7.7.1 MEA Market Value & Volume (2015–2022)
        • 7.7.2 MEA Market Value & Volume (2023-2031)
      • 7.8 MEA Market Value & Volume by Regions
        • 7.8.1 MEA Market Value & Volume Comparison by Region (2015–2022)
        • 7.8.2 MEA Market Value & Volume Comparison by Region (2023-2031)
      • 7.9 MEA Market Value & Volume by Drug Class
        • 7.9.1 MEA Market Value & Volume Comparison by Drug Class (2015–2022)
        • 7.9.2 MEA Market Value & Volume Comparison by Drug Class (2023-2031)
      • 7.10 MEA Market Value & Volume by Type
        • 7.10.1 MEA Market Value & Volume Comparison by Type (2015–2022)
        • 7.10.2 MEA Market Value & Volume Comparison by Type (2023-2031)
      • 7.11 MEA Market Value & Volume by Treatment Type
        • 7.12.1 MEA Market Value & Volume Comparison by Treatment Type (2015–2022)
        • 7.11.2 MEA Market Value & Volume Comparison by Treatment Type (2023-2031)
      • 7.12 MEA Market Value & Volume by Route of Administration
        • 7.12.1 MEA Market Value & Volume Comparison by Route of Administration (2015–2022)
        • 7.12.2 MEA Market Value & Volume Comparison by Route of Administration (2023-2031)
      • 7.13 MEA Market Value & Volume by End Users
        • 7.13.1 MEA Market Value & Volume Comparison by End Users (2015–2022)
        • 7.13.2 MEA Market Value & Volume Comparison by End Users (2023-2031)
      • 7.14 MEA Market Y-o-Y Growth Rate Comparison 2016–2031
        • 7.14.1 MEA Market Y-o-Y Growth Rate by Region
        • 7.14.2 MEA Market Y-o-Y Growth Rate by Drug Class
        • 7.14.3 MEA Market Y-o-Y Growth Rate by Type
        • 7.14.4 MEA Market Y-o-Y Growth Rate by Treatment Type
        • 7.14.5 MEA Market Y-o-Y Growth Rate by Route of Administration
        • 7.14.6 MEA Market Y-o-Y Growth Rate by End Users
      • 7.15 MEA Market Share Comparison 2015–2031
        • 7.15.1 MEA Market Share by Region
        • 7.15.2 MEA Market Share by Drug Class
        • 7.15.3 MEA Market Share by Type
        • 7.15.4 MEA Market Share by Treatment Type
        • 7.15.5 MEA Market Share by Route of Administration
        • 7.15.6 MEA Market Share by End Users
    • Chapter 8 Global Multiple Sclerosis Drugs Market Company Profiles
      • 8.1 Market Competition Scenario Analysis, By Company
      • 8.2 Competitor Landscape
      • 8.3 Company Share Analysis
      • 8.4 Company Profiles
        • 8.4.1 Bristol-Myers Squibb Company
          • 8.4.1.1 Company Overview
          • 8.4.1.2 Business Description
          • 8.4.1.3 Product Portfolio
          • 8.4.1.4 Key Financials
          • 8.4.1.5 Key Developments
          • 8.4.1.6 SWOT Analysis
        • 8.4.2 Sanofi
          • 8.4.2.1 Company Overview
          • 8.4.2.2 Business Description
          • 8.4.2.3 Product Portfolio
          • 8.4.2.4 Key Financials
          • 8.4.2.5 Key Developments
          • 8.4.2.6 SWOT Analysis
        • 8.4.3 Novartis AG
          • 8.4.3.1 Company Overview
          • 8.4.3.2 Business Description
          • 8.4.3.3 Product Portfolio
          • 8.4.3.4 Key Financials
          • 8.4.3.5 Key Developments
          • 8.4.3.6 SWOT Analysis
        • 8.4.4 Pfizer Inc.
          • 8.4.4.1 Company Overview
          • 8.4.4.2 Business Description
          • 8.4.4.3 Product Portfolio
          • 8.4.4.4 Key Financials
          • 8.4.4.5 Key Developments
          • 8.4.4.6 SWOT Analysis
        • 8.4.5 Teva Pharmaceutical Industries Ltd.
          • 8.4.5.1 Company Overview
          • 8.4.5.2 Business Description
          • 8.4.5.3 Product Portfolio
          • 8.4.5.4 Key Financials
          • 8.4.5.5 Key Developments
          • 8.4.5.6 SWOT Analysis
        • 8.4.6 Merck & Co., Inc.
          • 8.4.6.1 Company Overview
          • 8.4.6.2 Business Description
          • 8.4.6.3 Product Portfolio
          • 8.4.6.4 Key Financials
          • 8.4.6.5 Key Developments
          • 8.4.6.6 SWOT Analysis
        • 8.4.7 F. Hoffmann-La Roche Ltd.
          • 8.4.7.1 Company Overview
          • 8.4.7.2 Business Description
          • 8.4.7.3 Product Portfolio
          • 8.4.7.4 Key Financials
          • 8.4.7.5 Key Developments
          • 8.4.7.6 SWOT Analysis
        • 8.4.8 Biogen
          • 8.4.8.1 Company Overview
          • 8.4.8.2 Business Description
          • 8.4.8.3 Product Portfolio
          • 8.4.8.4 Key Financials
          • 8.4.8.5 Key Developments
          • 8.4.8.6 SWOT Analysis
        • 8.4.9 Other Key Players
    • Chapter 9 Research Methodology
      • 9.1 Research Methodology
      • 9.2 Primary Research
      • 9.3 Secondary Research
      • 9.4 Report Scope
    • Chapter 10 About Us
      • 10.1 Who we are:
    • Chapter 11 Disclaimer

    To learn more about this report, request for sample report

  • Inquiry Form

    • I wish to see a sample of this report because.




    • Request for Customization
      message

    Why Choose Us

    • 360 Degree Approach
    • Growth Consulting
    • 24/7 Research Support
    • Comprehensive-Level of Customization
    • Comprehensive-Level of Customization
    • Competitive Intelligence
    • Single-Country/ Region Intelligence
    • Post-Sale Service Assistance
    • Access to Lead Analysts
    • Available in PDF, Excel, Word/ PPT

  • Request for Customization

    • I wish to see a sample of this report because.




    • Request for Customization
      message

RELATED REPORTS

OUR CLIENTS

Don't just take our word. We are trusted by these great companies!

MARKET RESEARCH REPORTS

MarketResearch.Biz (Powered by Prudour Pvt. Ltd.) delivers customized research solutions by actuating its broad spectrum of research methodologies, databases, and resources, and this is further strengthened by our global experience in syndicated and customized industry projects.

Our tailor-made research services include quick market scans, country reports, in-depth market analysis, competition monitoring, consumer research and satisfaction studies, supplier research, growth planning, and quite a lot more.

SHORT NAVIGATION

CONTACT US

Copyright © 2021 Prudour Private Limited. All Rights Reserved.

Powered by Pvt. Ltd.

Speak to Analyst
×

Request a call

person
phone
email
message

Customer Care

+1 (347) 796-4335